The Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System is indicated for use: AUTOTRANSFUSION 1) for the collection of autologous blood from the patient's pleural cavity or mediastinal area for reinfusion purposes in trauma and post operative situations CHEST DRAINAGE - 1) to evacuate air and/or fluid from the chest cavity or mediastrinum - 2) to help prevent air and/or fluid from reaccumulating in the chest cavity or mediastinum - 3) to help re-establish and maintain normal intrathoracic pressure gradients - 4) to facilitate complete lung re-expansion to restore normal breathing dynamic.

Device Description

The Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System is a multi-chamber collection/reinfusion system. The Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System is a sterile, single use devices intended for the collection of autologous blood (autotransfusion) and as chest drainage collection units.

AI/ML Overview

The provided text describes a 510(k) submission for the Pleur-evac® Sahara Plus Continuous Reinfusion Autotransfusion System. However, it does not contain any information about acceptance criteria, device performance studies, sample sizes, expert involvement, or ground truth establishment relevant to the request.

The document confirms that this device is "substantially equivalent" to a previously marketed device (K963850) based on "a detailed device description, performance testing and conformance with consensus and voluntary performance standards." However, the details of these performance tests, including specific acceptance criteria and study results, are not elaborated upon in the provided sections.

Therefore, I cannot fulfill the request for information regarding acceptance criteria and the study that proves the device meets them because the necessary details are absent from the provided text.

Summary

{0}------------------------------------------------

JUL 2 5 2003

Section X 510 (K) Summary of Substantial Equivalence

In accordance with the requirements of 21 CFR § 807, this summary is formatted with the Agency's final rule "....510(k) Summaries and 510(k) Statements ...." and can be used to provide equivalence summary to anyone requesting it from the Agency.

Date Prepared:	March 24, 2003
Manufacturer	Genzyme BiosurgeryA division of GENZYME CORPORATION600 Airport RoadFall River, MA 02720
Contact Person	Denise LimaPhone: (508) 677-6439Fax: (508) 677-6667e-mail: denise.lima@genzyme.com
Device InformationTrade Name:	Pleur-evac® Sahara Plus ContinuousReinfusion Autotransfusion System
Common Name:	Continuous Reinfusion Autotransfusion System
Classification Name:	Autotransfusion Apparatus(per 21 CFR § 868.5830)

Indications for Use

The Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System is indicated for use:

AUTOTRANSFUSION

for the collection of autologous blood from the patient's pleural cavity or mediastinal area for reinfusion purposes in trauma and post operative situations

CHEST DRAINAGE

1. to evacuate air and/or fluid from the chest cavity or mediastrinum
1. to help prevent air and/or fluid from reaccumulating in the chest cavity or mediastinum
1. to help re-establish and maintain normal intrathoracic pressure gradients
1. to facilitate complete lung re-expansion to restore normal breathing dynamic.

{1}------------------------------------------------

Device Description

Substantial Equivalence

The Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System of this submission is similar in intended use, materials and performance characteristics of the currently marketed Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System (#K963850).

The determination of substantial equivalence for this device was based on a detailed device description, performance testing and conformance with consensus and voluntary performance standards.

{2}------------------------------------------------

Public Health Service

Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 5 2003

Genzyme Biosurgery c/o Ms. Denise Lima 600 Airport Road Fall River, MA 02720

Re: K031554

Pleur-evac® Sahara Plus Continuous Reinfusion Autotransfusion System Regulation Number: 868.5830 Regulation Name: Autotransfusion Apparatus Regulatory Class: Class II (two) Product Code: CAC Dated: May 16, 2003 Received: May 19, 2003

Dear Ms. Lima:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 - Ms. Denise Lima

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours.

KQaGTU

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number (if known) Device Name

Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System

Section II Indications for Use

Pleur-evac Sahara Plus Continuous Reinfusion Autotransfusion System is indicated for use:

AUTOTRANSFUSION

for the collection of autologous blood from the patient's pleural cavity or 1) mediastinal area for reinfusion purposes in trauma and post operative situations.

CHEST DRAINAGE

to evacuate air and/or fluid from the chest cavity or mediastinum 2)
to help prevent air and/or fluid from re-accumulating in the chest cavity or 3) mediastinum
to help re-establish and maintain normal intrathoracic pressure gradients, 4) and to facilitate complete lung re-expansion to restore normal breathing dynamics.

Voeertu

510(k) Number K031554

Prescription Use
(Per 21 CFR § 801.109)

Over-the-Counter Use _________________________________________________________________________________________________________________________________________________________

(Optional Format 1-2-96)

Regulation Number and Section

§ 868.5830 Autotransfusion apparatus.

(a)
Identification. An autotransfusion apparatus is a device used to collect and reinfuse the blood lost by a patient due to surgery or trauma.(b)
Classification. Class II (performance standards).